Lymphoma represents a heterogeneous disease both across and within histological subtypes. The future for the treatment of patients with lymphoma will involve matching a targeted therapy to the unique genetic and molecular composition of each lymphoma. This Review discusses biomarkers that can guide treatment decisions for patients with lymphoma, and explore the challenges and strategies for making biomarker-driven personalized medicine a reality in the cure and management of this disease.
- Andrew M. Intlekofer
- Anas Younes